Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2a Clinical Trial for the Evaluation of Safety and Efficacy of Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab for Patients With Gemcitabine-refractory Biliary Tract Cancer

Next Previous
Trial Profile

Phase 1/2a Clinical Trial for the Evaluation of Safety and Efficacy of Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab for Patients With Gemcitabine-refractory Biliary Tract Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; SMT NK (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors SMT bio

Most Recent Events

  • 06 Jun 2023 Results (between December 2019 and June 2021) assessing the safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with biliary tract cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
  • 28 Mar 2022 Status changed from recruiting to completed.
  • 10 Apr 2021 Interim results of phase 1/II study investigating Combinatorial allogeneic NK cell therapy with Pembrolizumab for cholangiocarcinoma presented at the 112th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top